Evaluation of antibiotic resistance rates in S. Aureus infections by years: A 6-year retrospective study (2019-2024) in IZMIR, TURKIYE
This six-year retrospective study in Izmir, Turkey, reveals a significant upward trend in antibiotic resistance for several key drugs against *S. aureus* infections between 2019 and 2024, highlighting the critical need for regular susceptibility testing and prudent antibiotic selection.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the invisible world of the human body, a single bacterium called Staphylococcus aureus is a constant presence. It lives quietly on the skin and in the noses of many people without causing harm. However, when this organism finds a way into the bloodstream, lungs, or deep tissues, it can turn into a formidable enemy, causing infections that range from minor skin rashes to life-threatening illnesses like pneumonia and heart valve infections. For decades, doctors have relied on antibiotics—powerful medicines designed to kill bacteria or stop them from multiplying—to fight these invasions. But bacteria are not static; they are living things that change and adapt. When antibiotics are used frequently, the bacteria that survive often develop defenses, becoming resistant to the very drugs meant to cure them. This phenomenon, known as antimicrobial resistance, is a growing global crisis. It means that medicines once considered reliable are becoming less effective, forcing doctors to use stronger, more expensive, and sometimes more toxic alternatives. Understanding how quickly these bacteria are changing is essential for keeping patients safe and ensuring that effective treatments remain available.
In a six-year retrospective study conducted in Izmir, Turkey, researchers set out to map the changing defenses of S. aureus against a wide array of antibiotics. They looked back at data collected from 2019 to 2024 from a major teaching hospital, examining thousands of bacterial samples taken from patients with various infections. The team analyzed how these bacteria responded to different drugs, tracking whether the resistance rates were climbing, falling, or staying the same over time. Their goal was to provide a clear picture of the current battlefield, helping medical professionals understand which weapons are still sharp and which have become dull.
The study revealed a troubling trend: the bacteria are becoming increasingly resistant to many common antibiotics. One of the most significant changes was seen with oxacillin, a drug often used to treat staph infections. In 2019, about 17 percent of the bacteria were resistant to it, but by 2024, that number had nearly doubled to almost 35 percent. Similar upward trajectories were observed for other frequently used drugs. Resistance to erythromycin, a common macrolide antibiotic, rose from roughly 15 percent to nearly 30 percent over the six years. Clindamycin, another staple in treating skin and soft tissue infections, saw its resistance rate climb from 11 percent to 22 percent. The situation was even more dramatic for fusidic acid, where resistance jumped from under 5 percent to over 20 percent, and for tetracycline, which saw its resistance rate more than double. These increases suggest that these drugs are losing their ability to reliably clear infections, likely due to their widespread use.
Not every drug followed this upward path. The researchers found that resistance to some antibiotics actually decreased or remained very low, offering a glimmer of hope. Gentamicin, an older antibiotic, saw its resistance rate drop from about 8.6 percent in 2019 to just 3.3 percent in 2024. Similarly, resistance to amikacin fell significantly, and the rates for trimethoprim-sulfamethoxazole showed a general decline, though with some fluctuation. Perhaps most reassuring was the performance of the "last-resort" drugs, such as vancomycin and teicoplanin, which are reserved for the most severe cases. Throughout the entire six-year period, resistance to these critical medications remained extremely low, hovering around 1 percent or less. This indicates that these powerful drugs are still highly effective against the vast majority of S. aureus strains in this region.
However, the study also highlighted that some antibiotics have become almost useless against this bacterium. Penicillin G, one of the earliest antibiotics discovered, showed resistance rates that were consistently above 85 percent, peaking at nearly 99 percent in the early years of the study. Ampicillin fared only slightly better, with an average resistance rate of over 60 percent. The data showed that these drugs are no longer viable options for treating S. aureus infections unless a specific lab test confirms the bacteria are susceptible. The researchers also noted that for certain newer or less commonly tested drugs, such as norfloxacin and fosfomycin, there was no resistance detected at all in the samples they reviewed, suggesting these could be valuable alternatives, though more data is needed to confirm their reliability.
The analysis confirmed that these changes were not random fluctuations but represented a clear, significant shift over time. The patterns of resistance were dynamic, with some drugs losing effectiveness rapidly while others held steady. This underscores the importance of continuous monitoring. Doctors cannot rely on old assumptions about which drugs will work; they must test the specific bacteria causing a patient's infection to choose the right treatment. The study concludes that while some antibiotics are still effective, the rising tide of resistance to common drugs is a serious warning. It calls for careful stewardship of antibiotics to preserve the few tools that still work and to prevent the bacteria from becoming resistant to the last-resort medications that currently remain effective.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.